On November 18th, Boya Collection (Beijing) Biotechnology Co., Ltd. (hereinafter referred to as: Boya Collection, English name: EdiGene) gene editing and treatment base - Guangzhou Jiyin Medical Technology Co., Ltd. (Note: Boya Collection Guangzhou Company) It was officially launched in the Nansha Industrial Park of Guangdong Medical Valley. The base follows international GMP standards and has established a high-level ultra-clean laboratory for cell preparation and gene editing in accordance with the development and production process of Boyaa series. According to reports, the EA-01, a gene editing and treatment product designed to cure beta thalassemia, will be clinically promoted here. The Boya Collection was introduced by the founder Wei Wensheng, where the R&D center was set up in Guangzhou. The main reason is that “patients are here, partners are here, the environment is good, and Nansha has given a lot of support. We believe that the project can bloom in Nanshaâ€. According to the "Chinese Thalassemia Blue Book (2016)", relevant data show that there are about 300,000 people with severe and intermediate thalassemia in China, and about 30 million people with "thalassaemia" genes. Among them, Guangdong, Guangdong, Taiwan and other provinces and cities have more than 10% of the "thalassaemia" gene carriers, and even more than 20% in Guangxi. The products developed by Burson-Marsteller include gene editing therapies for hereditary diseases such as beta thalassemia gene editing therapy, and universal CAR-T (chimeric antigen receptor T cell immunotherapy) therapy for cancer treatment. . Among them, Boya series uses CRISPR/Cas9 gene editing technology for gene editing therapy ET-01 for β-thalassemia, which is also the fastest-growing product of Boya series and is expected to enter clinical research in 2019. Wei Wensheng said that because this is a genetic editing technology for single-gene genetic diseases, the patient population is relatively accurate, so it is expected to be approved soon after three years of clinical trials, and may achieve cornering overtaking in the field of global gene editing and treatment of diseases. Today, this top-of-the-line therapy is about to achieve GMP mass production at its Nansha production site. The Boya Collection published a keynote report by Dr. Wei Dong, CEO, explaining the opportunities and challenges facing the company. In his view, gene editing technology has a very good application prospect, and global genetic editing commercial development has just begun. As the first genetic editing company in China, Boya is the world's leading genetic editing company because it will closely follow the two main lines of gene editing and treatment of diseases and new drug research and development. The establishment of the Guangzhou company, the series of medical treatment and the establishment of the Guangzhou Gene Editing and Treatment Base is a very important step, marking the beginning of EdiGene's new phase from scientific research. CEO Wei Dong led the guests to visit the GMP workshop (Source: Enterprise for the picture) On the same day, Boya Collection was founded by Wei Wensheng, deputy director of the Management Committee of Nansha Development Zone (Nansha District of the Free Trade Zone), Xie Ming, dean of the Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, and a medical partner, “China’s thalassemiaâ€. Li Chunfu, the father of the company, Qiu Lili, the founder of the Angel Mother Charity Fund, which has long been concerned about the thalassemia patients, and Xu Cong, executive vice president of Eli Lilly Asia Fund, delivered speeches at the ceremony. Founded in 2015, Boya Collection is a bio-tech company specializing in genome editing. It has high-efficiency genome editing technology, advanced high-throughput genetic screening platform, and a robust gene knockout cell library dedicated to disease patients and medicine. And diagnostic companies, basic research provides a variety of products and services. At the same time, Boya Collection cooperates with medical companies and medical peers to develop new treatments for cancer, genetic diseases and infectious diseases. In August of this year, the company officially announced the completion of the billion-yuan Pre-B round of financing, led by Lilly Asia Fund, Huagai Capital and investment, the company A round of leading investors IDG Capital, China Economic Cooperation and Gong Hongjia and other investors continue to vote.
Our PET anti slip tape is made of premium
PET material and selected aluminum oxide grit, coated with special upgraded solvent
acrylic adhesive. It has super strong durability, long lasting high adhesion, uniform
sand surface, good waterproof ability. It can be used instead of 3M 600 series,
function and quality are similar, but the price is much more economical.
Service life of our PET anti slip tape is 2 years. It is perfect to be used for
flat surfaces, steps, stairways, entrances, ramps, ladders, lawn equipment, snowmobiles,
scooters, construction machinery and vehicles, other machinery and vehicles
It
has different colors, such as black, transparent, grey, yellow, yellow/black,
etc. Other colors also can be customized.
The width ranges from 10mm to 1070mm, the length can be 2meters to 120.2meters.
PET anti slip tape, anti slip grip tape, 3M anti slip tape, safety-walk slip resistant tape, safety walk anti slip tape Kunshan Jieyudeng Intelligent Technology Co., Ltd. , https://www.jerrytape.com
PET Anti Slip Tape
